Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Alpha Cognition's share price for the quarter that ended in Mar. 2024 was $0.58. Alpha Cognition's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 156.93 Mil. Therefore, Alpha Cognition's market cap for the quarter that ended in Mar. 2024 was $91.02 Mil.
Alpha Cognition's quarterly market cap
increased
from Sep. 2023 ($31.33 Mil) to Dec. 2023 ($58.73 Mil) and
increased
from Dec. 2023 ($58.73 Mil) to Mar. 2024 ($91.02 Mil).
Alpha Cognition's annual market cap
declined
from Dec. 2021 ($66.93 Mil) to Dec. 2022 ($14.54 Mil) but then
increased
from Dec. 2022 ($14.54 Mil) to Dec. 2023 ($58.73 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Alpha Cognition's Enterprise Value for Today is $90.65 Mil.
Alpha Cognition Market Cap Historical Data
The historical data trend for Alpha Cognition's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Alpha Cognition's Market Cap
For the Biotechnology subindustry, Alpha Cognition's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's Market Cap distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's Market Cap falls into.
Alpha Cognition Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Alpha Cognition's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Cognition (OTCPK:ACOGF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Alpha Cognition Market Cap Related Terms
Thank you for viewing the detailed overview of Alpha Cognition's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Alpha Cognition (Alpha Cognition) Business Description
Alpha Cognition Inc is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, and Cognitive Impairment with Mild Traumatic Brain Injury (mTBI) for which there are limited or no treatment options. The Company is focused on the development of ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and completed an NDA filing to the FDA in September 2023. The company anticipates an FDA approval in mid-2024. The Company's ALPHA-1062 development program is primarily focused on clinical and regulatory development, Chemistry, Manufacturing and Control (CMC) development, and commercial readiness.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACOGF has been successfully added to your 